Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 701–800 of 3,636
Vicente-Valor, J., García‐González, X., Ibáñez-García, S., Durán-García, M. E., de Lorenzo‐Pinto, A., Rodríguez, C., Méndez, I., Percovich-Hualpa, J. C., Alonso, A. H., & Sanjurjo‐Sáez, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112519 · Cited by 30
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
Samuel, E., Watford, M., Egolum, U. O., Ombengi, D., Ling, H., & Cates, D. W. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221105169 · Cited by 34
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Chong, E. W., Joncas, F., Seidah, N. G., Calon, F., Diorio, C., & Gangloff, A. (2022) · BMC Cancer · doi:10.1186/s12885-022-10120-6 · Cited by 33
Statin associated muscle symptoms: An update and review
Dicken, W., Mehta, A., Karagiannis, A. D., Jain, V., Vavuranakis, M., Sperling, L. S., & Cassimatis, D. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.010 · Cited by 31
Ibrahim, S., Reeskamp, L. F., de Goeij, J. N., Hovingh, G. K., Planken, R. N., Bax, W. A., Min, J. K., Earls, J. P., Knaapen, P., Wiegman, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae028 · Cited by 33
Zafrir, B., Saliba, W., & Flugelman, M. Y. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.57133 · Cited by 33
High-Risk Coronary Plaque Features: A Narrative Review
Dawson, L. P., & Layland, J. J. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00271-9 · Cited by 34
“Second, PCSK-9 inhibitors have demonstrated similar improvements in reducing CV events and also improve plaque morphology, but are limited by higher costs [59, 87].”
BackgroundJones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 34
“Alirocumab treatment resulted in a relative risk reduction of 15% for ASCVD events compared to the placebo in acute coronary syndrome patients on statin therapy [61].”
BackgroundGibson, C. M., Duffy, D., Bahit, M. C., Chi, G., White, H. D., Korjian, S., Alexander, J. H., Lincoff, A. M., Heise, M. A., Kingwell, B. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae614 · Cited by 29
Self-citationMechanisms Underlying Vascular Inflammaging: Current Insights and Potential Treatment Approaches
Zeng, Y., Buonfiglio, F., Li, J., Pfeiffer, N., & Gericke, A. (2025) · Aging and Disease · doi:10.14336/ad.2024.0922 · Cited by 43
“Alirocumab significantly reduced the incidence of the primary endpoint, driven mainly by reductions in MI and ischemic stroke [179].”
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
“Furthermore, in patients with atherosclerotic CVD, evolocumab or alirocumab added to moderate-intensity or high-intensity statin therapy with or without ezetimibe resulted in a >40% reduction in apoB levels 268,269 .”
Self-citationPCSK9 — A Journey to Cardiovascular Outcomes
Burnett, J. R., & Hooper, A. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1813758 · Cited by 27
Proprotein convertase subtilisin/kexin type 9 in kidney disease
Schmit, D., Fliser, D., & Speer, T. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz122 · Cited by 29
Shaya, F. T., Sing, K., Milam, R., Husain, F., del Aguila, M. A., & Patel, M. Y. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00379-9 · Cited by 30
“Similar considerations may also be important in patients with recent ACS because of the high risk for subsequent events in the months following an event [12, 23].”
BackgroundTada, H., Okada, H., Nomura, A., Takamura, M., & Kawashiri, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-019-1183-4 · Cited by 30
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 34
“In addition, a high-intensity statin regimen with the maximum tolerated dose was required as background therapy [6, 12] (Table 1).”
BackgroundFamilial hypercholesterolemia: Detect, treat, and ask about family
Shah, N. P., Ahmed, H. M., & Tang, W. H. W. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19021 · Cited by 32
Current Status of Dyslipidemia Treatment for Stroke Prevention
Aradine, E., Hou, Y., Cronin, C. A., & Chaturvedi, S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01052-4 · Cited by 28
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 33
The Role of Statins in Current Guidelines
Rached, F. H., & Santos, R. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00861-9 · Cited by 32
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
Selvaraj, S., Claggett, B. L., Packer, M., Zannad, F. M., Anand, I. S., Pieske, B. M., Zhao, Z., Shi, V. C., Lefkowitz, M. P., McMurray, J. J. V., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022069 · Cited by 30
The prognostic significance of the lipid profile after an ischemic stroke
Vitturi, B. K., & Gagliardi, R. J. (2021) · Neurological Research · doi:10.1080/01616412.2021.1967677 · Cited by 32
“Two randomized clinical trials demonstrated that the use of potent PCSK9 inhibitors had a significant additional benefit over statin therapy, in which they were found to result in more than 50% additional reduction in LDL cholesterol and provide an additional 25% reduction in cardiovascular risk in patients with ather…”
BackgroundDiscovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction
Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 30
Rizos, C. V., Skoumas, I., Rallidis, L. S., Skalidis, E. I., Τζιόμαλος, Κ., Garoufi, A., Anagnostis, P. G., Sfikas, G., Kotsis, V., Doumas, M. N., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.10.024 · Cited by 30
Kim, K., Hong, S., Han, K., & Park, C. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155327 · Cited by 33
Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
Paquette, M., Faubert, S., Saint-Pierre, N., Baass, A. W., & Bernard, S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.12.002 · Cited by 32
Vallejo‐Vaz, A. J., Ray, K. K., Ginsberg, H. N., Davidson, M. H., Eckel, R. H., Lee, L. V., Bessac, L., Pordy, R. C., Letierce, A., & Cannon, C. P. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.008 · Cited by 30
Self-citationTherapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Bellis, A., Gioia, G. D., Mauro, C., Mancusi, C., Barbato, E., Izzo, R., Trimarco, B., & Morisco, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132968 · Cited by 29
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 32
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
Broch, K., Lemström, K., Gustafsson, F., Eiskjær, H., Karason, K., Gjesdal, G., Fagerland, M., Pentikäinen, M., Lommi, J., Gude, E., et al. (2024) · JACC. Heart failure · doi:10.1016/j.jchf.2024.04.026 · Cited by 29
Disruption of PCSK9 Suppresses Inflammation and Attenuates Abdominal Aortic Aneurysm Formation
Peng, Z., Lv, S., Chen, H., Rao, H., Guo, Z., Wan, Q., Yang, J., Zhang, Y., Liu, D., Chen, H., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320391 · Cited by 30
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 36
Self-citationIntensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
Lee, Y., Lee, S. J., Kim, J. W., Lee, S., Kim, G.-S., Park, J. H., Cho, J., Kang, W. C., Yoon, H., Kim, W., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600283 · Cited by 40
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
Kosmas, C. E., Silverio, D., Sourlas, A., Garcia, F., Montan, P. D., & Guzman, E. (2018) · Drugs in Context · doi:10.7573/dic.212562 · Cited by 33
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.06.001 · Cited by 42
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
Parhofer, K. G., von Stritzky, B., Pietschmann, N., Dorn, C., & Paar, W. D. (2019) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-0158-0 · Cited by 28
“These data are also similar to an alirocumab expanded use program reporting a 55.1% LDL-C reduction from baseline to week 24 in patients with HeFH and/or CHD in the USA who received alirocumab 150 mg Q2W [23], an audit study that reported a 49% LDL-C reduction in 105 PCSK9 AE adverse event, LDL low-density lipoprotein…”
InfluentialUse of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
Warden, B. A., Kaufman, T. M., Minnier, J., Duell, P. B., Fazio, S., & Shapiro, M. D. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2019.09.026 · Cited by 33
Stock, J. K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.023 · Cited by 33
Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
Dayoub, E. J., Eberly, L. A., Nathan, A. S., Khatana, S. A. M., Adusumalli, S., Návar, A. M., Giri, J. S., & Groeneveld, P. W. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019331 · Cited by 36
“levels: (1) patients with concurrent highintensity statin use, (2) patients highly adherent to a highintensity statin, and (3) patients highly adherent to a highintensity statin with measured serum LDL- C ≥70 mg/dL.”
BackgroundCollet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 44
Self-citationSecondary Prevention of Cardiovascular Disease in Women: Closing the Gap
Thakkar, A., Agarwala, A., & Michos, E. D. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.24 · Cited by 31
Yi, S., An, S. J., Park, H., Yi, J., & Ohrr, H. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac029 · Cited by 31
Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review
Masson, W. M., Lobo, M., Barbagelata, L., Molinero, G., Bluro, I. M., & Nogueira, J. P. (2022) · Vascular Medicine · doi:10.1177/1358863x221091320 · Cited by 31
Suchowerska, A. K., Stokman, G., Palmer, J. T., Coghlan, P. A., Pieterman, E. J., Keijzer, N., Lambert, G. C., Chemello, K., Jaafar, A. K., Parmar, J., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100293 · Cited by 28
“Coincubation of lymphocytes with PCSK9 D374Y and alirocumab, a monoclonal antibody against PCSK9 (12), restored LDLR expression at the cell plasma membrane (Fig.”
BackgroundThe German Lipoprotein Apheresis Registry—Summary of the ninth annual report
Schettler, V. J. J., Peter, C., Zimmermann, T. P., Julius, U., Roeseler, E., Schlieper, G., Heigl, F., Grützmacher, P., Löhlein, I., Klingel, R., et al. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13780 · Cited by 28
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
Choi, H. D., & Kim, J. H. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/7362551 · Cited by 33
Wu, L., Kong, Q., Huang, H., Xu, S., Qu, W., Zhang, P., Yu, Z., & Luo, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1127534 · Cited by 29
“Proprotein convertase subtilisin/kexin type-9 inhibitor (PCSK9i) lower LDL levels by approximately 60% (Sabatine et al., 2017; Schwartz et al., 2018).”
BackgroundThe Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 32
Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1649394 · Cited by 28
Kristiansen, O., Vethe, N. T., Peersen, K., Wang Fagerland, M., Sverre, E., Prunés Jensen, E., Lindberg, M., Gjertsen, E., Gullestad, L., Perk, J., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa076 · Cited by 27
Farkouh, M. E., Godoy, L. C., Brooks, M. M., Mancini, G. B. J., Vlachos, H. A., Bittner, V., CHAITMAN, B. R., Siami, F. S., Hartigan, P. M., Frye, R. L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.536 · Cited by 30
Self-citationGrafeneder, J., Derhaschnig, U., Eskandary, F. A., Buchtele, N., Sus, N., Frank, J., Jilma, B., & Schoergenhofer, C. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200139 · Cited by 33
Bittner, V., Schwartz, G. G., Bhatt, D. L., Chua, T. S. J., Silva, H. A. D., Díaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., McGinniss, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.04.122 · Cited by 33
Self-citationFang, Q., Lu, X., Zhu, Y., Lv, X., Yu, F., Ma, X., Liu, B., & Zhang, H. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101614 · Cited by 36
“48,49 Moreover, inclisiran targets PCSK9 production inhibition and typically requires administration once every 6 months.”
Lee, Y., Hong, B., Yun, K. H., Kang, W. C., Hong, S. J., Lee, S., Lee, S., Hong, S., Ahn, C., Kim, J., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3911 · Cited by 34
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Corsini, A., Ginsberg, H. N., & Chapman, M. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108812 · Cited by 28
Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 34
“74 Evolocumab and alirocumab are two human monoclonal antibodies (mAbs) that target the catalytic domain of PCSK9 and prevent it from binding to LDLR. 75 , 76 By reducing LDL -”
Steg, P. G., Szarek, M. J., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.071269 · Cited by 32
Self-citationNanna, M. G., Návar, A. M., Wang, T. Y., Li, S., Virani, S. S., Li, Z., Robinson, J. G., Roger, V. L., Wilson, P. W. F., Goldberg, A. C., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.05.009 · Cited by 29
Pérez‐Calahorra, S., Laclaustra, M., Marco-Benedí, V., Pintó, X., Sánchez-Hernández, R. M., Plana, N., Ortega, E., Fuentes, F. J., & Civeira, F. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1153-x · Cited by 28
Jia, X., Ramsey, D. J., Rifai, M. A., Ahmed, S. T., Akeroyd, J. M., Dixon, D. L., Gluckman, T. J., Nambi, V., Ballantyne, C. M., Petersen, L. A., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.12.030 · Cited by 28
Alder, M., Bavishi, A. A., Zumpf, K. B., Peterson, J., & Stone, N. J. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.056 · Cited by 26
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1787832 · Cited by 28
“MACE is a heterogeneously defined composite outcome that often includes interventions and may be susceptible to bias [64,65].”
BackgroundInfluentialThe role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Vavuranakis, M., Jones, S. R., Cardoso, R. N., Gerstenblith, G., & Leucker, T. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.09.016 · Cited by 29
An, J., Zhang, Y., Muntner, P., Moran, A. E., Hsu, J. W., & Reynolds, K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017310 · Cited by 30
Tada, H., Takamura, M., & Kawashiri, M. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266249 · Cited by 37
Fischer, L. T., Hochfellner, D. A., Knoll, L., Pöttler, T., Mader, J. K., & Aberer, F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01283-w · Cited by 28
“Both, the FOURIER trial on evolocumab and the ODYSSEY OUTCOMES trial on alirocumab showed that PCSK9 inhibitors were not only capable to significantly lower LDL-C levels, but also result in a substantial reduction of the cardiovascular event rate without relevant risk of adverse events [5, 6].”
BackgroundResultInfluentialDounousi, E. C., Tellis, C. C., Pavlakou, P., Duni, Α., Liakopoulos, V., Mark, P. B., Papagianni, A. A., & Tselepis, A. D. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6677012 · Cited by 32
“In large clinical trials, PCSK9i manage to reduce LDL-C to target levels and Lp(a) levels by 20-30% with additional cardiovascular benefit when added to statin treatment in high-risk populations [14].”
BackgroundExtreme cardiovascular risk—do we need a new risk category?
Dyrbuś, K., Gąsior, M., Penson, P. E., & Banach, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab771 · Cited by 27
Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Tzanaki, I., Agouridis, A. P., & Kostapanos, M. S. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.119 · Cited by 31
A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021
Wei, N., Hu, Y., Liu, G., Li, S., Yuan, G., Shou, X., Zhang, X., Shi, J., & Zhai, H. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101151 · Cited by 29
LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA
Pan, Y., Wangqin, R., Li, H., Jin, A., Li, J., Lin, J., Meng, X., Xian, Y., Laskowitz, D. T., & Wang, Y. (2022) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001317 · Cited by 26
Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway
Zhu, W., Ding, C., Huang, P., Ran, J., Lian, P., Tang, Y., Dai, W., & Huang, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-09610-1 · Cited by 30
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 30
Puri, R., Mehta, V., Duell, P. B., Wangnoo, S. K., Rastogi, A., Mohan, V., Zargar, A. H., Kalra, S., Sahoo, A., Iyengar, S. S., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.002 · Cited by 34
Future prospects for human genetics and genomics in drug discovery
Ghoussaini, M., Nelson, M. R., & Dunham, I. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102568 · Cited by 30
“These evidence combined led to development of PCSK9 inhibitors and by 2017 two (alirocumab and evolocumab) were approved by the FDA to treat patients with high cholesterol unresponsive to statins or diet [15] [16] [17].”
BackgroundLiu, H., Li, J., Liu, F., Huang, K., Cao, J., Chen, S., Li, H., Shen, C., Hu, D., Huang, J., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad111 · Cited by 29
Kumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 28
“Pivotal evidence of CV benefit emerged from the FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) trials, both of which successfully reached the primary endpoint [50,51].”
BackgroundKraler, S. C., Wenzl, F. A., Vykoukal, J. V., Fahrmann, J. F., Shen, M., Chen, D., Chang, K., Chang, C., von Eckardstein, A., Räber, L., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.014 · Cited by 31
Lee, S., Cha, J., Choi, W., Lee, W. S., Jeong, J., Choi, S., Cho, Y.-H., Park, W., Yoon, C.-H., Lee, Y., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2222 · Cited by 26
Katsiki, N., Filippatos, T. D., Vlachopoulos, C. V., Panagiotakos, D. B., Milionis, H. J., Tselepis, A. D., Garoufi, A., Rallidis, L. S., Richter, D. J., Nomikos, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.01.004 · Cited by 29
AlTurki, A., Marafi, M., Dawas, A., Dubé, M., Vieira, L., Sherman, M. H., Grégoire, J. C., Thanassoulis, G., Tardif, J., & Huynh, T. T. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.011 · Cited by 25
Wilkins, J. T., Gidding, S. S., & Robinson, J. G. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000644 · Cited by 29
Mortensen, M. B., Blaha, M. J., & Nordestgaard, B. G. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4759 · Cited by 27
Minno, M. N. D. D., Gentile, M., Minno, A. D., Iannuzzo, G., Calcaterra, I. L., Buonaiuto, A., Taranto, M. D. D., Giacobbe, C., Fortunato, G., & Rubba, P. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.02.018 · Cited by 26
The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease
Roman, Y. M., Hernández, A. V., & White, C. M. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020922994 · Cited by 29
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 30
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 29
Self-citationBroader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach
Fularski, P., Czarnik, W., Dąbek, B., Lisińska, W., Radzioch, E., Witkowska, A., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105212 · Cited by 30
“These results provide robust evidence for the efficacy of PCSK9 inhibitors in reducing cardiovascular risk in patients with recent ACS [102,103].”
ResultAchievement of LDL-C <55 mg/dL among US adults: Findings from the cvMOBIUS2 registry
Návar, A. M., Shah, N. P., Shrader, P., Thomas, L. E., Ahmad, Z., Allred, C., Chamberlain, A. M., Chrischilles, E. A., Dhalwani, N. N., Effron, M. B., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.06.012 · Cited by 58
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 31
“They demonstrated a 50–60% reduction in LDL-C and reduced ASCVD mortality in the FOURIER and ODYSSEY OUTCOMES trials, respectively [20,21].”
BackgroundKraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf037 · Cited by 33
Buja, L. M., Zehr, B., Lelenwa, L. C., Ogechukwu, E., Zhao, B., Dasgupta, A., & Barth, R. F. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.107153 · Cited by 29
Coca, A., Kreutz, R. H., Manolis, A. J., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002464 · Cited by 27
Tada, H., Usui, S., Sakata, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17040 · Cited by 27
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 32
Cainzos‐Achirica, M., Bittencourt, M. S., Osei, A. D., Haque, W. Z., Bhatt, D. L., Blumenthal, R. S., Blankstein, R., Ray, K. K., Blaha, M. J., & Nasir, K. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.10.016 · Cited by 25
Self-citation
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

